Replimune Group (FRA:7R8) EBIT: €-262.73 Mil (TTM As of Mar. 2026)

What is Replimune Group EBIT?

Replimune Group FRA:7R8 -3.56% 32 EBIT is €-262.73 Mil as of Mar. 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Replimune Group's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-61.05 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-262.73 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Replimune Group's annualized ROC % for the quarter that ended in Mar. 2026 was -388.36%. Replimune Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -574.31%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Replimune Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -39.08%.

Replimune Group (FRA:7R8) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Replimune Group's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-252.136 * ( 1 - 0.33% )	/	( (62.339	+	67.08)	/ 2 )
=	-251.3039512	/	64.7095
=	-388.36 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	284.886	-	25.899	-	( 229.843	-	max(0, 42.774	-	239.422	+	229.843	))
=	62.339

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	287.516	-	29.365	-	( 232.589	-	max(0, 50.367	-	241.438	+	232.589	))
=	67.08

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Replimune Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-244.208	/	( ( (42.984 + max(-32.239, 0))	+	(42.06 + max(-39.423, 0)) )	/	2 )
=	-244.208	/	( ( 42.984	+	42.06 )	/	2 )
=	-244.208	/	42.522
=	-574.31 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	7.055)	-	(25.899	+	0	+	13.395)
=	-32.239

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	7.449)	-	(29.365	+	0	+	17.507)
=	-39.423

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Replimune Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-262.725	/	672.351
	=	-39.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Replimune Group EBIT Related Terms

Replimune Group EBIT Historical Data

* Premium members only.

The historical data trend for Replimune Group's EBIT can be seen below:

Replimune Group EBIT Chart

Replimune Group Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

EBIT

Get a 7-Day Free Trial

-105.16

-158.63

-192.03

-221.02

-264.37

Replimune Group Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-66.83	-73.43	-69.09	-59.15	-61.05

FRA:7R8 vs AVTX, KURA, SANA: EBIT Comparison

For the Biotechnology subindustry, Replimune Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Replimune Group EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Replimune Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Replimune Group's EV-to-EBIT falls into.

Save Embed

32GF Score

Replimune Group Inc FRA:7R8

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Replimune Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-262.73 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €-262.73 Mil mean?

Replimune Group (FRA:7R8) has a EBIT of €-262.73 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Replimune Group.

Is Replimune Group's EBIT too high?

Replimune Group's current EBIT is €-262.73 Mil. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Replimune Group's EBIT compare to AVTX and KURA?

Replimune Group's EBIT of €-262.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Replimune Group. Replimune Group's current EBIT is €-262.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Replimune Group stock overvalued right now?

Replimune Group (FRA:7R8) has a current EBIT of €-262.73 Mil. The current EBIT is €-262.73 Mil. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current EBIT is €-262.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Replimune Group Business Description

Industry Healthcare Biotechnology

Comparable Companies AVTX KURA SANA ANRO ORIC DRTS OLMA LBRX MRVI SLDB VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges REPL:USA

Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801

Website https://www.replimune.com

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

32GF Score

Get the complete analysis for FRA:7R8

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.22

Price

View FRA:7R8 Analysis

See EBIT data for all stocks →